Dosing & Uses
Dosage Forms & Strengths
- ~75mm in diameter and 0.75mm thick
An allogeneic, cellularized scaffold product indicated for topical (nonsubmerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults; not intended to provide root coverage
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Respiratory tract infection (2%)
Upper respiratory tract infection (2%)
Aphthous stomatitis (2%)
Oral pain (2%)
Mouth injury (2%)
Facial hypoesthesia (2%)
Do not use if oral infection present
Known allergies to bovine products
Hypersensitivity reactions possible; monitor for both early and later signs of hypersensitivity reaction following application; evaluate and treat signs and symptoms of potential allergic reactions according to standard practice; if necessary, remove Gintuit as part of the treatment for the allergic reaction
Monitor for signs and symptoms of wound infection; signs of surgical site infection may include pain, edema, erythema, drainage, odor, warmth, or fever; the diagnosis of wound infection may be complicated by the white or yellow appearance of the cellular sheet after it becomes hydrated with wound fluid
Safety of this product for oral administration has not been evaluated beyond 6 months; long-term potential for oral mucosal cancers to arise from, or in response to, this product is unknown
Transmission of infection
- Contains cells derived from donated human newborn foreskin tissue
- Transmission of infectious diseases may occur
- The foreskin donor’s mother was tested and found negative for human pathogens, including antibodies to HIV-1 and HIV-2, HTLV-1 and HTLV-2, HAV, HBV, HBsAg, HCV, WNV, EBV, CMV, and syphilis; also tested for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma
- Product manufacture also includes reagents derived from animal materials, including bovine pituitary extract; all animal-derived reagents are tested for viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma before use; bovine materials are sourced to minimize bovine spongiform encephalopathy, the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease (vCJD); vCJD has never been attributed to use of any medical product manufactured with BPE, but the theoretical possibility cannot be dismissed
- Only shipped after passing primary test results from in-process microbial tests
- A final sterility test is initiated prior to shipping, but the result will not be available for up to 14 days; if microbial contamination is detected after the product has been shipped, the manufacturer will notify health care providers and recommend appropriate actions
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Unknown whether distributed in breast milk
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Does not function as a tissue graft
The mechanism of action by which Gintuit increases keratinized tissue at the treated site has not been identified
For single patient use only
Used as 1 application over a surgically created vascular wound bed in the oral cavity
Adjust the size of the cellular sheet for the size of the wound bed
The safety and efficacy of repeat application(s) have not been established
Prepare the surgical site following local anesthesia by surgically creating a vascular wound bed with viable wound edges and establish adequate hemostasis
Prepare the cellular sheet by checking the following
- Examine the sealed polybag for leaks, damage, or contamination
- Verify expiration date (product expires at 11:59 PM ET on the date of expiration)
- Verify product pH (6.8-7.7) is within the acceptable range, using the agarose gel medium pH color chart
- Do not open the polybag until the surgical site has been prepared
- Use within 15 minutes of opening the sealed polybag
See full prescribing information for a detailed, illustrated description on how to apply the cellular sheet to the prepared surgical site
Handle cellular sheet in aseptic manner
Do not use if there is evidence of contamination, visible particulates, or pungent odor
As supplied, Gintuit is not a biohazardous material; however, follow your local guidelines for disposal of any remaining cellular sheet
To maintain cell viability, store in the sealed polybag at 68-73°F (20-23°C) in its shipping box with all insulating components intact until use
Do not freeze or refrigerate, sterilize, or incubate
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.